Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mir-200b-3p agomir is a **synthetic, chemically-modified double-stranded RNA molecule** designed to mimic the mature endogenous microRNA miR-200b-3p, thereby increasing its activity within cells[3][9]. miR-200b-3p is a member of the miR-200 family of microRNAs, well known for regulating epithelial-mesenchymal transition (EMT), inhibiting tumor metastasis via direct inhibition of the ZEB1/2 transcription factors, and targeting other genes such as HMGB3, SMAD2, MAGP2, and TUBB3, among others[4][2]. As an agomir, this molecule is used to upregulate the effects of miR-200b-3p, which include **inhibiting EMT, suppressing tumor cell proliferation, invasion, and migration**, and improving **chemosensitivity (e.g., to 5-fluorouracil in colorectal cancer cells)** by downregulating HMGB3/\u03b2-catenin/c-Myc signaling[2][4]. miR-200b-3p also regulates NF-\u03baB and IRF3-mediated interferon production by targeting TBK1, indicating a role in antiviral immunity, although the agomir itself is typically used in cancer research rather than antiviral therapy[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mir-200b-3p agomir.